A study performed in mice with breast cancer bone metastases secreting sclerostin, pharmacological treatment with an anti-sclerostin antibody (Setrusumab) was shown to reduce bone metastatic burden, protect against breast cancer-induced bone destruction, and inhibit tumor cell dissemination to other distant sites. Here, SOST is linked to breast carcinoma.